International Journal of Hematology and Oncology 2021, Vol 31, Num 4 Page(s): 096-102
Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology

Aydın CILTAS1, Suleyman BUYUKBERBER1, Turkan O. TOPCU2, Mehmet KUCUKONER3, Ummugul UYETURK4, Sener CIHAN5, Mehmet A. SENDUR6, Burcin BUDAKOGLU7, Umut KEFELI8, Ramazan YILDIZ1, Gamze GOKSEL9, Veli BERK10, Ozan BALAKAN11, Berna OKSUZOGLU7, Dogan UNCU6, Ugur COSKUN1, Feyyaz OZDEMIR2, Mustafa BENEKLI1

1Gazi University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Karadeniz University Faculty of Medicine, Department of Medical Oncology, Trabzon, TURKEY
3Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir, TURKEY
4Abant Izzet Baysal University Faculty of Medicine, Department of Medical Oncology, Bolu, TURKEY
5Okmeydanı Training and Research Hospital, Department of Medical Oncology, Istanbul, TURKEY
6Ankara Numune Training and Research Hospital , Department of Medical Oncology, Ankara, TURKEY
7Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
8Medeniyet University Goztepe Training and Research Hospital, Department of Medical Oncology, Istanbul, TURKEY
9Celal Bayar University Faculty of Medicine, Department of Medical Oncology, Manisa, TURKEY
10Erciyes University Faculty of Meedicine, Department of Medical Oncology, Kayseri, TURKEY
11Gaziantep University Faculty of Medicine, Gaziantep, Department of Medical Oncology, TURKEY

Keywords: Advanced gastric cancer, Cisplatin, Capecitabine, Efficacy, Toxicity
Gastric cancer is an important public health problem which comprises 10% of all cancers and 12% of all cancer related deaths all over the world. Because of differences in patient populations and treatment schemes in various studies, standard practice of advanced stage gastric cancer has not been fully established. The aim of this study was to assess the use of cisplatin and capecitabine combination regimen in real-world clinical practice. Medical records of 76 male and 37 female metastatic gastric cancer patients treated with first-line cisplatin and capecitabine combination between February 2006 and December 2009 were retrospectively analyzed in 11 centers of Anatolian Society of Medical Oncology. Patients previously treated with chemotherapy were excluded from the analysis. The median age of the patients was 64 years (range, 28-83). Seventy-six (67.2%) patients were males and 37 (32.7%) females. Most of the patients were metastatic (n= 85, 75.2%) at the time of initial diagnosis. The most common sites for metastasis were liver (65.9%), lung (11.3%), peritoneum (23.8%) and local recurrence (15.9%) with multiple metastases in 9.7% of the patients. The mean follow-up period of all patients was 41 months (range 12-61). ORR was 33.6%, while disease control rate (DCR) was 72.6 %. Median PFS was 4.7 months (95%CI 3.75- 6.49) and median OS was 11.1 months (95%CI 5.58- 10.98). The most common grade 3-4 adverse events were anemia (8.3%), nausea-vomiting (3.8%) and diarrhea (1.8%). In terms of efficacy, toxicity and convenience, cisplatin and capecitabine combination is effective and well tolerated in Turkish patients with advanced gastric cancer, and could be one of the standard regimens for the first-line treatment in this cohort.